Overview of Imarem

Quick Facts

Property	Description
Active ingredient	Imatinib mesylate (Imatinib)
Form	Film-coated tablet
Pharmacological class	Tyrosine Kinase Inhibitor (TKI)
General purpose	Molecular control of abnormal cell proliferation
Origin	Synthetic small-molecule compound
Classification	Prescription Drug (Rx)

What is Imarem and Its Composition?

Imarem is a specific prescription-only medication brand manufactured by Remedica Ltd. (Cyprus) that contains the active substance Imatinib mesylate, which is the mesylate salt of the compound Imatinib. This drug is classified as a synthetic small-molecule product, created entirely through chemical synthesis and primarily supplied as a film-coated tablet designed for oral administration.

Its composition is a single-active-ingredient product. The small-molecule nature of Imatinib is a feature supported by pharmacological studies and allows for reliable absorption and systemic distribution after oral intake.

What Type of Targeted Therapy is Imatinib?

Imatinib is classified as a Protein Kinase Inhibitor, specifically belonging to the specialized class of Tyrosine Kinase Inhibitors (TKIs). This designation identifies it as an advanced targeted antineoplastic therapy used to combat abnormal cell growth.

Imatinib is clinically recognized for its unique ability to achieve molecular control by blocking the signaling pathways of specific, hyperactive proteins, such as the BCR-ABL fusion protein, that drive disease proliferation. This function establishes Imatinib as a pioneer in the era of highly focused treatments, differentiating it from earlier, less selective systemic agents.

What is the General Purpose of This Medicine?

The general purpose of this medicine is to establish and maintain molecular control over diseases characterized by the excessive and uncontrolled growth of specific cells. As a selective inhibitor, Imarem's function is to interrupt the pathological growth signals that sustain the underlying disease, a mechanism recognized in clinical literature. This signal blockade provides a focused method to suppress the disease process and manage the resulting abnormal cell burden.

Regulatory References

Imatinib | StatPearls

What side effects are possible with Imarem?

Imarem: Possible Side Effects and Safety Information

Adverse Reaction Profile

Commonly reported adverse reactions (occurring in ge 30% of patients in clinical trials) include edema (fluid retention), nausea, vomiting, diarrhea, muscle cramps, musculoskeletal pain, rash, fatigue, and abdominal pain. Other frequently observed events span system-organ classes such as gastrointestinal, musculoskeletal, skin, and blood and lymphatic systems.

Serious and Clinically Significant Risks

Imarem carries the potential for several serious, clinically significant adverse reactions. These include: severe fluid retention (edema) which may require intervention; severe hepatotoxicity, with reports of fatal outcomes, necessitating regular liver function testing; and severe congestive heart failure and left ventricular dysfunction, especially in patients with pre-existing cardiac risk factors. The drug is associated with cytopenias (low blood counts, including anemia, neutropenia, and thrombocytopenia) requiring frequent complete blood count monitoring. Less common but serious risks also include Grade 3/4 hemorrhage, gastrointestinal perforations, and severe bullous dermatologic reactions (e.g., Stevens-Johnson syndrome).

Population-Specific Safety Considerations and Restrictions

Imarem is not recommended during pregnancy due to the risk of fetal harm; women of childbearing potential and male patients must use effective contraception during and following treatment. Growth retardation has been reported in children and adolescents, requiring close and regular monitoring of their growth. Safety monitoring protocols require initial and periodic checks of liver function, renal function, and frequent hematological testing. Patients should also be monitored for signs of fluid retention (e.g., rapid weight gain) and hypothyroidism (in patients post-thyroidectomy).

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile of Imatinib mesylate by detailing the specific clinical manifestations observed in case reports. An overdose may present initially with a cluster of gastrointestinal symptoms, including nausea, vomiting, diarrhea, and abdominal pain. Other signs of overdosage documented in official sources include rash, swelling, headache, extreme tiredness (fatigue), and muscle cramps or spasms.

Overdosage at high dose levels (e.g., 1200 mg to 2000 mg per day) is associated with the development of pronounced cytopenia. Furthermore, severe outcomes, including decreased kidney function, liver failure, and death, have been reported in case summaries following prolonged exposure to excessive doses.

In the event of a known or suspected overdosage, regulatory guidance mandates that immediate medical attention must be sought. For severe presentations, such as collapse, seizure, or trouble breathing, contacting emergency services immediately is required. Management is strictly limited to appropriate symptomatic and supportive treatment, as no specific antidote is known. Due to the drug’s high plasma protein binding, dialysis is officially noted as being unlikely to be an effective removal procedure. Patient observation is a necessary component of the official response protocol.

Therapeutic Uses of Imarem

Quick Facts: Imarem Therapeutic Domains

Chronic Myeloid Leukemia (CML): Used in newly diagnosed patients, as well as those in the blast crisis, accelerated phase, or chronic phase after the failure of prior therapy.
Acute Lymphoblastic Leukemia (ALL): Employed for Philadelphia chromosome-positive (Ph+) ALL in combination with other treatments or as monotherapy in relapsed/refractory cases.
Other Conditions: Appropriate for certain myelodysplastic/myeloproliferative diseases (MDS/MPD), advanced hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), and unresectable or metastatic dermatofibrosarcoma protuberans (DFSP).

Imarem is a prescription medicine that may be used to address several specific medical conditions. It is indicated for the management of various forms of cancer of the white blood cells, including Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML). This includes its use in adult and pediatric patients with newly diagnosed CML, as well as those in advanced phases of the disease or who did not respond to initial treatments.

It is also used to treat Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL). For newly diagnosed Ph+ ALL, the medication is often integrated with standard chemotherapy regimens.

Furthermore, Imarem has indications for the treatment of certain adult patients with specific myelodysplastic/myeloproliferative diseases (MDS/MPD). The drug is also appropriate for some patients with hypereosinophilic syndrome (HES) or chronic eosinophilic leukemia (CEL) that involve a particular genetic rearrangement. Finally, it may be used to treat unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans (DFSP), a rare type of soft tissue sarcoma.

Regulatory References

EMA therapeutic overview

Eligibility and Restrictions for Use

The eligibility profile for Imarem is defined by regulatory standards (FDA, EMA) that classify populations as permitted, restricted, or contraindicated.

Populations Not Permitted (Contraindications)

The absolute restriction is for patients with a known hypersensitivity to imatinib mesylate or any component of the formulation, for whom use is contraindicated.

Age and General Eligibility

Imarem is officially allowed for use in adult patients and pediatric patients for specific labeled oncologic conditions. The geriatric population is eligible without a required age-based dose adjustment. However, safety and efficacy are not established for children under approximately one or two years of age (varies by regional label).

Conditional and Restricted Use

Use is highly conditional in specific physiological states. Imarem is generally not recommended during pregnancy and women must not breastfeed while undergoing treatment. Furthermore, patients with severe hepatic impairment require close monitoring; regulatory documents specify that these patients should receive a lower starting dose. Caution is also advised for patients with severe renal impairment due to limited clinical data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Imarem (Imatinib mesylate) describes specific interaction patterns related primarily to its role in the body’s metabolic processes.

Imatinib is documented as both a major substrate for its own metabolism, primarily by the CYP3A4 enzyme, and a potent inhibitor of this enzyme. It also acts as an inhibitor of CYP2D6 and CYP2C9.

Classification	Officially Documented Interacting Substances
Increased Imatinib Levels	Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir, Voriconazole)
Decreased Imatinib Levels	Strong CYP3A4 Inducers (e.g., Rifampin, St. John’s wort)
Increased Co-drug Levels	CYP3A4 Substrates with a narrow therapeutic window (e.g., Pimozide, Fentanyl, Sirolimus, Cyclosporine)

Co-administration with strong CYP3A4 inducers, including the herbal product St. John’s wort, is formally advised to be avoided due to the documented risk of significantly lowered Imatinib plasma concentrations. The consumption of grapefruit juice is also officially advised to be avoided as it may increase Imatinib levels.

Regulatory restrictions apply to specific combinations: Cobimetinib, Conivaptan, and Dihydroergotamine are officially listed as contraindicated. Patients requiring anticoagulation are formally advised to receive low-molecular weight or standard heparin instead of warfarin.

Official documents also note that hepatic impairment may slow the drug’s clearance, potentially altering its interaction profile.

Mechanism of Action

Molecular Inhibition of Target Kinases

Imatinib functions as a highly specific competitive inhibitor that targets the BCR-ABL fusion protein and other growth-promoting enzymes like c-KIT and PDGFRA/B. The molecule binds precisely to the adenosine triphosphate (ATP) binding pocket of these targets, locking the enzymes in an inactive conformation and immediately halting their ability to transfer phosphate groups.

Cellular Pathway Interruption and Apoptosis

This molecular intervention suppresses the aberrant signaling that sustains cell proliferation. The sudden loss of kinase activity interrupts critical signal transduction cascades (like PI3K/Akt and RAS/MAPK) that are essential for the survival and growth of the target cells. This deprivation of pro-survival signals forces the affected cells to undergo programmed cell death (apoptosis), while also arresting their continuous division. This mechanism leads to the selective reduction of the targeted cell population.

Constraints on Mechanistic Efficacy

Biological constraints limit the completeness of the cellular effect. These include the emergence of kinase domain mutations (e.g., T315I), which prevent Imatinib binding, and the presence of quiescent (non-dividing) stem cells which are less susceptible to signal blockade. These factors define the physiological boundaries of the mechanism.

Dosage and Administration Information

How to Use Imarem (Imatinib)

Imarem is a prescription-only medication administered according to established protocols that define the route, dose, and specific conditions for intake. This section outlines the standardized usage protocol for the medication.

Administration Protocol

The approved route of administration for Imarem is oral. The medicine is supplied as 100 mg and 400 mg film-coated tablets.

Usage Constraint	Instruction
Timing Relative to Meals	Must be taken with a meal and a large glass of water.
Standard Frequency	Doses of 400 mg and 600 mg are taken once daily. The 800 mg dose is split into 400 mg twice daily (morning and evening).
Duration	Generally continuous until disease progression. For adjuvant GIST, a treatment course of 3 years is specified.

Dosing Rules

The initial daily dose is determined by the specific medical condition being addressed. For adult patients, common starting doses include 400 mg (e.g., Chronic Myeloid Leukemia Chronic Phase) or 600 mg (e.g., Chronic Myeloid Leukemia Accelerated Phase). The highest daily dose is 800 mg for specific indications.

Special Administration Instructions

Difficulty Swallowing: If unable to swallow the tablet whole, it may be dispersed in a glass of still water or apple juice and must be consumed immediately after dissolution.
Missed Dose: If a dose is missed, it should not be taken; the next scheduled dose should be taken at the usual time.
Population Adjustment: A reduction in the initial starting dose, such as to 300 mg daily, is recommended for patients with severe hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Imarem

Research into Imatinib for Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) is primarily based on large-scale, long-term randomized controlled trials and observational follow-up studies.

Research for Newly Diagnosed CML in Chronic Phase

The research framework in CML was established through major, multinational Randomized Controlled Trials (RCTs). These studies evaluated Imatinib alongside the therapy that was previously standard. Researchers examined outcomes related to Molecular Response and Cytogenetic Response, and monitored the time without progression to more aggressive phases. Long-term studies, tracking patients for more than 10 years, contribute to understanding the long-term patterns measured. What remains uncertain is the full extent of comparative data, as many patients in comparator groups later switched to Imatinib.

Research for Advanced and Previously Treated CML

For CML patients in the advanced phases or those whose disease was observed following prior therapy failure, available research relies on smaller, multi-center trials. The studies monitored outcomes related to Hematological and Cytogenetic Response, but there is limited comparative evidence in this specific, high-risk setting.

Evidence for Use in Acute Lymphoblastic Leukemia (Ph+ ALL)

The research for Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) often involves studies where Imatinib was evaluated in combination with standard, intensive chemotherapy. Research included both newly diagnosed adults and pediatric patients. The evidence often reflects the group patterns observed with the combination regimen, making it complex to isolate the specific patterns related to Imatinib alone.

Evidence for Rare Cancers and Genetic Conditions

For rare conditions, such as specific myelodysplastic/myeloproliferative diseases (MDS/MPD) with the PDGFR gene rearrangement and advanced Dermatofibrosarcoma Protuberans (DFSP), research is based on small-scale, prospective studies. These studies monitored Hematological and Molecular Remission or Objective Response Rate (ORR). However, sample sizes were modest due to the rarity of the conditions.

Findings describe group patterns, not personal outcomes; research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Imarem (FAQ)

Q: Can you drink coffee or caffeine while taking Imarem?

A: Official regulatory documents do not contain a specific warning about consuming coffee or caffeine while taking this medication. However, official information does advise against consuming grapefruit juice, as it is known to increase the concentration of the medicine in the bloodstream, which could raise the risk of side effects.

Q: Do you have to take Imarem with food or on an empty stomach?

A: The official administration protocol states that this medication must be taken with a meal and a large glass of water. Taking it with a meal is required according to the administration protocol, which may help minimize the risk of gastrointestinal irritation.

Q: How long can someone safely stay on Imarem treatment?

A: The duration of treatment depends on the specific condition being addressed, according to regulatory documents. For Chronic Myeloid Leukemia (CML), treatment is generally prescribed to be continuous unless the disease progresses or side effects occur. For specific conditions like adjuvant GIST, a defined treatment course of 3 years is specified.

Q: Are there any major food or drink restrictions while using Imarem?

A: Yes, official regulatory documents advise that certain substances should be avoided. Patients are advised to avoid consuming grapefruit juice and the herbal product St. John’s wort because they can significantly interact with the medication and affect its levels in the body.

Q: Can Imarem be crushed or split if it's a tablet?

A: Dispersion in liquid is an administration option for those with difficulty swallowing. The official regulatory documents do not provide instruction for crushing or splitting the tablet for routine use.

Q: How does Imarem work at a cellular level?

A: This medication is a tyrosine kinase inhibitor. At a cellular level, it works by binding to and blocking specific proteins (kinases) that drive cell growth and multiplication in certain diseases. This interruption of signals is intended to lead to the affected cells undergoing programmed cell death.

Q: Is Imarem a new or established medication?

A: Based on its regulatory history, the active ingredient in this medicine, imatinib mesylate, is considered an established pioneer in the class of targeted therapies known as tyrosine kinase inhibitors for cancer treatment.

Q: Why do some people say Imarem didn't work for them?

A: Regulatory and clinical evidence recognizes that there are constraints on the effectiveness of this medicine. One documented reason for reduced efficacy is the emergence of kinase domain mutations in the disease cells, which can prevent the drug from binding to its target and working correctly.

Q: Does Imarem cause weight gain or weight loss?

A: Official regulatory information lists weight gain as a very common adverse reaction. This is often associated with fluid retention (edema), which is a safety concern that should be monitored by a healthcare professional.

Q: Is Imarem safe to take if I already have liver problems?

A: Official prescribing information states that patients with severe hepatic impairment (severe liver problems) should receive a lower initial starting dose and require close monitoring due to the risk of severe liver toxicity.

Q: What happens if I forget to take my Imarem dose?

A: Official administration protocols state that if a patient misses a scheduled dose, they should not take the missed dose. Instead, they should take their next dose at the usual scheduled time.

Q: Will Imarem affect my ability to drive or operate machinery?

A: Official regulatory documents advise patients to use caution when performing skilled tasks. The medication can cause side effects such as dizziness, blurred vision, or sleepiness, which may affect one's ability to drive or operate machinery safely.

Q: What are the signs of a serious, but rare, side effect from Imarem?

A: Signs of potentially serious, though rare, side effects, as described in regulatory documents, include: unusual, rapid weight gain (suggesting severe fluid retention), yellowing of the skin or eyes (jaundice), or any signs of unexplained bleeding or easy bruising.

Q: How long does Imarem stay in your system after you stop taking it?

A: According to the pharmacokinetics information in regulatory documents, the elimination half-life of the active substance is approximately 18 hours. Its major active metabolite, which is also active, has a longer half-life of about 40 hours.

Q: Can Imarem cause changes in mood or sleep?

A: The official adverse reaction profile lists insomnia (difficulty sleeping) as a common side effect. Less common, but officially reported, is a confusional state.

Q: Is there a generic version of Imarem available?

A: Yes, based on official drug records, the active ingredient, imatinib mesylate, is available in generic formulations in the United States and other regions.

Q: Does Imarem cause stomach upset or nausea?

A: Yes, regulatory documents list common gastrointestinal issues. Nausea, vomiting, and diarrhea are specifically listed as very common adverse reactions associated with this medication.

Q: What are the storage requirements for Imarem?

A: To maintain drug stability, official guidelines require the medicine to be stored at controlled room temperature (generally 20 C to 25 C). It must also be kept in its original container and protected from moisture.

Q: What should I do if I think I'm having an allergic reaction to Imarem?

A: Official patient counseling information notes that signs of a serious allergic reaction, such as swelling of the face, lips, tongue, or throat, require immediate professional assessment.

Q: Will Imarem affect the results of any common blood tests?

A: The drug is known to cause cytopenias (low blood counts); therefore, changes in common tests like the Complete Blood Count (CBC) are expected. For this reason, official safety protocols require frequent hematological monitoring.

Q: Does Imarem come in different strengths?

A: Yes, according to official product information, the medicine is supplied as 100 mg and 400 mg film-coated tablets for oral use.

Q: How do I know if the Imarem I have is expired?

A: The expiration date is printed on the container label or packaging. Official regulatory guidelines state that the product must be disposed of according to controlled pharmaceutical waste procedures after this date.

Q: Can Imarem be used by people with kidney issues?

A: Official documents note that caution must be exercised when the medication is administered to patients with severe renal impairment (severe kidney issues) due to limited clinical data. Monitoring of renal function is officially required during therapy.

Q: Is Imarem safe for people with high blood pressure?

A: Official regulatory documents indicate that the drug has been associated with high blood pressure (hypertension) and may affect cardiac function. Therefore, official safety protocols require that patients with pre-existing high blood pressure be monitored.

Q: Is Imarem a controlled substance?

A: No, based on official drug schedules and regulatory classifications, the active ingredient imatinib mesylate is not classified as a federally controlled substance.

How should Imarem be stored and disposed of?

How to Store and Dispose of Imarem?

The storage and disposal instructions for Imarem (Imatinib mesylate) are officially determined by regulatory agencies to maintain drug stability and ensure environmental safety.

Official Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature, generally 20 C to 25 C.
Protection	Keep protected from moisture and excessive heat.
Container	Keep the medicine in its original, tight container or blister packaging.
Child Safety	Keep out of the sight and reach of children.

Official Disposal Instructions

To dispose of unused or expired Imarem, regulatory guidelines prohibit placing it in household trash or public wastewater systems. Instead, the medication must be taken to a designated collection point, such as a local pharmacy, for controlled pharmaceutical waste disposal according to local regulations.

Imarem